| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 13/05/2024 | 07:30 | Business Wire | Oregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur... | NASDAQ:LTRN | Lantern Pharma Inc |
| 09/05/2024 | 22:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:LTRN | Lantern Pharma Inc |
| 09/05/2024 | 22:02 | Business Wire | Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights | NASDAQ:LTRN | Lantern Pharma Inc |
| 06/05/2024 | 09:00 | Business Wire | Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism | NASDAQ:LTRN | Lantern Pharma Inc |
| 02/05/2024 | 13:30 | Business Wire | Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET | NASDAQ:LTRN | Lantern Pharma Inc |
| 24/04/2024 | 14:00 | Business Wire | Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development | NASDAQ:LTRN | Lantern Pharma Inc |
| 22/04/2024 | 14:12 | Business Wire | Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan | NASDAQ:LTRN | Lantern Pharma Inc |
| 18/03/2024 | 21:02 | Business Wire | Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights | NASDAQ:LTRN | Lantern Pharma Inc |
| 18/03/2024 | 12:12 | IH Market News | Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks | NASDAQ:LTRN | Lantern Pharma Inc |
| 15/03/2024 | 13:00 | Business Wire | Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 | NASDAQ:LTRN | Lantern Pharma Inc |
| 11/03/2024 | 12:30 | Business Wire | Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET | NASDAQ:LTRN | Lantern Pharma Inc |
| 05/03/2024 | 14:01 | Business Wire | Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference | NASDAQ:LTRN | Lantern Pharma Inc |
| 04/03/2024 | 14:01 | Business Wire | Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines | NASDAQ:LTRN | Lantern Pharma Inc |
| 01/03/2024 | 03:54 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:LTRN | Lantern Pharma Inc |
| 15/02/2024 | 14:01 | Business Wire | Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers | NASDAQ:LTRN | Lantern Pharma Inc |
| 17/01/2024 | 13:30 | Business Wire | Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer | NASDAQ:LTRN | Lantern Pharma Inc |
| 29/12/2023 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LTRN | Lantern Pharma Inc |
| 01/12/2023 | 12:02 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:LTRN | Lantern Pharma Inc |
| 30/11/2023 | 14:00 | Business Wire | FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) | NASDAQ:LTRN | Lantern Pharma Inc |
| 08/11/2023 | 22:01 | Business Wire | Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights | NASDAQ:LTRN | Lantern Pharma Inc |
| 01/11/2023 | 13:00 | Business Wire | Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET | NASDAQ:LTRN | Lantern Pharma Inc |
| 10/10/2023 | 14:00 | Business Wire | Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET | NASDAQ:LTRN | Lantern Pharma Inc |
| 03/10/2023 | 14:00 | Business Wire | Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma | NASDAQ:LTRN | Lantern Pharma Inc |
| 25/09/2023 | 14:30 | Business Wire | Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors | NASDAQ:LTRN | Lantern Pharma Inc |
| 18/09/2023 | 15:00 | Business Wire | Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas | NASDAQ:LTRN | Lantern Pharma Inc |
| 31/08/2023 | 14:00 | Business Wire | Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting | NASDAQ:LTRN | Lantern Pharma Inc |
| 28/08/2023 | 14:00 | Business Wire | Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors | NASDAQ:LTRN | Lantern Pharma Inc |
| 14/08/2023 | 14:30 | Business Wire | Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT | NASDAQ:LTRN | Lantern Pharma Inc |
| 09/08/2023 | 22:01 | Business Wire | Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights | NASDAQ:LTRN | Lantern Pharma Inc |
| 02/08/2023 | 14:00 | Business Wire | Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET | NASDAQ:LTRN | Lantern Pharma Inc |